Cynapsus closes private placement
Cynapsus Therapeutics (TSX-V:CTH) has closed a brokered private placement of 3.4 million units at a price of 5 cents a unit to raise gross proceeds of $170,000 for working capital purposes. Each Unit...
View ArticleCynapsus drug one of top ten neurology projects
Cynapsus Therapeutics’ (TSX-V:CTH) APL-130277 for Parkinson’s disease was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee, including Dr. Harry Tracy,...
View ArticleCynapsus files short-form prospectus
ynapsus Therapeutics (TSX-V:CTH) has filed a preliminary short-form prospectus with the securities regulatory authorities in British Columbia, Alberta and Ontario in connection with a best-effort...
View ArticleCynapsus gets Notice of Allowance for oral Parkinson’s drug patent
Cynapsus Therapeutics (TSX-V:CTH) has received a notice of allowance from the U.S. Patent and Trademark Office for the patent application covering critical claims directed to thin film compositions...
View ArticleCynapsus files short form prospectus
Cynapsus Therapeutics (TSX-V:CTH) has received a receipt for its final short form prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta...
View ArticleCynapsus closes $6-million offering
Cynapsus Therapeutics (TSX-V:CTH) has completed a short-form prospectus offering of units for gross proceeds of slightly more than$6-million. Michael J. Fox Concurrent with the closing of the offering,...
View ArticleCynapsus continues prospectus offering
Cynapsus Therapeutics (TSX-V:CTH) is continuing its previously announced offering under a short-form prospectus. On March 1, the company completed a closing for gross proceeds of $6,008,000, achieving...
View ArticleCynapsus closes second tranche of offering
Cynapsus Therapeutics (TSX-V:CTH) has completed a second closing of its short-form prospectus offering of units for gross proceeds of $1.3-million, following the first closing of $6-million on March 1,...
View ArticleCynapsus names Dexcel execs to its board
Tomer Gold, VP of R&D, of closely-held Dexcel Pharma, and Ilan Oren, VP of business development at Dexcel, have joined the board of Cynapsus Therapeutics (TSX-V:CTH). Dexcel recently acquired...
View ArticleZacks starts Cynapsus at buy
Zachs Research has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and price target of $1.25, calling the company an “undiscovered gem.” The stock was quoted at 40 cents...
View ArticleNoble starts Cynapsus at buy
Noble Financial Capital Markets has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and 12-month price target of $1.75. The stock closed at 38 cents on Monday. Cynapsus is...
View ArticleCynapsus to start trading on OTCQX International
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) common shares have been approved for trading in the U.S. on the OTCQX marketplace, with trading to commence immediately under the symbol CYNAF. Trading...
View ArticleCynapsus names Nan Hutchinson to board
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Nan Hutchinson to its board. Nan Hutchinson Over the past decade, Ms. Hutchinson was the SVP of marketing and sales for URL Pharma, helping...
View ArticleCynapsus PD data: couldn’t have wished for anything better
Anthony Giovinazzo “If I had asked for a gift, I couldn’t have wished for anything better,” says Anthony Giovinazzo, president and CEO of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH). He was...
View ArticleCynapsus gains DTC approval
Common shares of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) have been made eligible for book-entry delivery and depository services of The Depository Trust Co. (DTC) to facilitate electronic...
View ArticleCynapsus finds 25-mg APL-130277 strip safe
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive interim data from its recently completed healthy volunteer pilot study of a single 25-milligram sublingual strip (APL-130277) dose...
View ArticleCynapsus files for financing
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a preliminary short-form prospectus with securities agencies in the provinces of British Columbia, Alberta and Ontario for a best-efforts...
View ArticleCynapsus files final short-form prospectus for offering
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a final short-form prospectus in British Columbia, Alberta and Ontario to sell a minimum of 23,076,923 units and a maximum of 38,461,538 units...
View ArticleCynapsus reports positive study data for APL-130277
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose...
View ArticleCynapsus sees no irritation in APL-130277 animal test
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) says there was no irritation observed when testing its APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters,...
View Article
More Pages to Explore .....